Home
Business
Corporate Finance
Asset Management
Wealth Management
Global Markets
Structured Finance
Research
Daily Note
Market Strategy
Macroeconomics
Securities Analysis
Customer Trading
Stock Trading
Futures Trading
Options Trading
Company News
About CMBI
Company Profile
Join Us
Contact Us
English
Simplified Chinese
Traditional Chinese
English
Home
>
Research
>
Securities Analysis
【Company Research】I-Mab BioPharma (IMAB US) – Amendment on the deal regarding anti-CD47 antibodies with AbbVie
Click to read the report